A metalloproteinase inhibitor prevents acute graft-versus-host disease while preserving the graft-versus-leukaemia effect of allogeneic bone marrow transplantation Journal Article


Authors: Hattori, K.; Hirano, T.; Oshimi, K.; Yagita, H.; Okumura, K.
Article Title: A metalloproteinase inhibitor prevents acute graft-versus-host disease while preserving the graft-versus-leukaemia effect of allogeneic bone marrow transplantation
Abstract: Tumor necrosis factor (TNF) and Fas ligand (FasL) have been implicated in the pathogenesis of graft-versus-host disease (GVHD). Several recent studies have shown that some metalloproteinase mediates TNF-α and FasL processing. We examined the ameliorating effect of a hydroxamic acid-based metalloproteinase inhibitor (KB-R7785) that inhibits TNF-α and FasL release in a lethal acuteGVHD model in mice. The ameliorating effect of KB-R7785 was superior to that of anti-TNF-α antibody. We also examined the effect of KB-R7785, which we previously demonstrated a potent ameliorating effect on acute GVHD, on graft-versus-leukemia (GVL) effect of allogeneic bone marrow transplantation (BMT). Administration of KB-R7785 without bone marrow cells and spleen cells (BMS) significantly prolonged the survival of IgE-producing B53 hybridoma cell-inoculated (C57BL/6 x BALB/c) F1 (CBF1) mice by inhibiting the infiltration of B53 cells into the liver and spleen. Transplantation of B6 BMS without KB-R7785 resulted in the death of most recipients due to acute GVHD while efficiently eliminating B53 cells. Administration of KB-R7785 along with B6 BMS resulted in 50% survival of B53-inoculated CBF1 mice over 50 days without histological manifestations of acute GVHD or residual B53 cells. These results suggest that KB-R7785 could be a potent therapeutic agent for GVHD, and indicate the beneficial effects of KB-R7785 that inhibit tumor infiltration and prevent acute GVHD while preserving the GVL effect of allogeneic BMT.
Keywords: controlled study; transplantation, homologous; unclassified drug; pathogenesis; nonhuman; animals; mice; animal tissue; cell survival; protease inhibitors; cell infiltration; fas ligand; animal experiment; animal model; allogenic bone marrow transplantation; histology; b-lymphocytes; death; tumor necrosis factor-alpha; membrane glycoproteins; graft versus host reaction; hydroxamic acids; fas ligand protein; bone marrow cell; hybridoma; tumor growth; bone marrow transplantation; graft vs host disease; graft versus leukemia effect; glycine; tumor necrosis factor; spleen cell; immunoglobulin e; allogeneic transplantation; hydroxamic acid derivative; graft vs leukemia effect; bmt; metalloproteinase inhibitor; hybridomas; acute gvhd; metalloendopeptidases; priority journal; article; preservation of gvl; prevention of gvhd; 4 (n hydroxyamino) 2 isobutyl 3 methylsuccinyl phenylglycine n methylamide; [4 (n hydroxyamino) 2 isobutyl 3 methylsuccinyl]phenylglycine n methylamide
Journal Title: Leukemia and Lymphoma
Volume: 38
Issue: 5-6
ISSN: 1042-8194
Publisher: Taylor & Francis Group  
Date Published: 2000-01-01
Start Page: 553
End Page: 561
Language: English
PUBMED: 10953977
PROVIDER: scopus
DOI: 10.3109/10428190009059275
DOI/URL:
Notes: Export Date: 18 November 2015 -- Source: Scopus
Altmetric
Citation Impact
BMJ Impact Analytics
MSK Authors
  1. Koichi Hattori
    18 Hattori